| Similar Articles |
|---|
 |
The Motley Fool
February 18, 2005
Charly Travers |
A Drug to Get Your Blood Pumping Encysive's Thelin combines low risk with high sales potential.   |
The Motley Fool
December 7, 2006
Brian Lawler |
The Best Small Cap for 2007: Encysive Pharmaceuticals This little drug maker has the potential for big profit, in both the U.S. and Europe. Investors, take note. |
The Motley Fool
December 10, 2010
Brian Orelli |
Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered. |
The Motley Fool
January 28, 2008
Brian Lawler |
Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin? |
The Motley Fool
September 14, 2006
Brian Lawler |
Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note. |
The Motley Fool
May 28, 2009
Robert Steyer |
Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena. |
The Motley Fool
March 28, 2008
Brian Lawler |
Pfizer Gets the Signal to Steal Pfizer's acquisition of Encysive Pharmaceuticals is set for Monday. |
The Motley Fool
May 30, 2008
Brian Lawler |
Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products. |
The Motley Fool
December 17, 2010
Brian Orelli |
An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%. |
The Motley Fool
August 2, 2007
Brian Lawler |
United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note. |
The Motley Fool
June 2, 2006
Brian Lawler |
Encysive Can Breathe Easier The pharmaceutical's crucial Thelin drug gains EU approval. Encysive's next critical hurdle lies here in the U.S. Whatever the FDA's decision, expect more volatility in Encysive shares. |
The Motley Fool
December 12, 2005
Stephen D. Simpson |
Heavy Breathing for Myogen Positive data from a phase 3 drug study sends shares of this biotech much higher. |
The Motley Fool
August 4, 2005
Charly Travers |
This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note. |
The Motley Fool
June 18, 2007
Brian Lawler |
Gilead Gets the Payoff Gilead gets marketing approval for one of its drug candidates. Investors, take note. |
The Motley Fool
March 7, 2007
Brian Lawler |
Encysive's Outback Adventures The pharmaceutical gains marketing approval for its lead compound in Australia. Investors, take note. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
August 7, 2007
Brian Lawler |
Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential. |
The Motley Fool
February 21, 2007
Brian Lawler |
Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note. |
Chemistry World
September 20, 2006
Victoria Gill |
`Silent Killer' as Treatment for Heart and Lung Disease Carbon Monoxide (CO), a gas once dubbed the `silent killer' by the UK's health and safety executive, could provide a life-saving treatment for an incurable lung and heart condition, report researchers. |
The Motley Fool
January 18, 2005
Charly Travers |
Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc. |
Nursing
December 2009
Vincent M. Vacca |
On the Alert for Pulmonary Arterial Hypertension Progressive and ultimately fatal, pulmonary arterial hypertension is a disease of the pulmonary arterial vasculature with no known cause. |
Managed Care
March 2006
Thomas Morrow |
Sharp Strategy Needed with New Treatment Options for PAH As another treatment for pulmonary hypertension nears approval, insurers should adopt a stepped-care approach. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
May 26, 2009
Brian Orelli |
Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected. |
Bio-IT World
October 14, 2004
Malorye A. Branca |
Taking Care of Business Artemis has been catering to life science users for more than 20 years, but even newcomers such as IntraLinks are finding a good niche for software products initially developed for financial services and other sectors. |
